GlassScriptPhysician profile
Charles C Shang
NPI 1104805902
$1,945.90
in general payments reported to CMS, 2019-2025
30 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $667 · 2023: $251 · 2024: $132 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $296.29 | 2021-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $271.18 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $175.28 | 2021-2023 | Creon |
| Glaxosmithkline, LLC. | $159.51 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.12 | 2021-2022 | |
| Exact Sciences Corporation | $137.05 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $129.99 | 2021-2024 | |
| Stryker Corporation | $75.91 | 2022 | |
| Pfizer INC. | $65.88 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $41.48 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.25 | 2022-2023 | |
| Almatica Pharma LLC | $30.41 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $29.41 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.09 | 2023 | Rytary |
| Corcept Therapeutics | $27.39 | 2025 | Korlym |
| Sobi, INC | $26.54 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.86 | 2025 | Zonisade |
| Philips North America LLC | $19.42 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.96 | 2023 | Opsumit, Uptravi |
| Kyowa Kirin, INC. | $17.10 | 2021 | |
| Neurocrine Biosciences, INC. | $16.23 | 2022 | |
| Abbott Laboratories | $16.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.89 | 2023 | Quviviq |
| Sun Pharmaceutical Industries INC. | $15.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.25 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.73 | 2022 | |
| Dexcom, INC. | $13.35 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Shang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.